Signalling in pancreatic cancer: from pathways to therapy

J Drug Target. 2023 Dec;31(10):1013-1026. doi: 10.1080/1061186X.2023.2274806. Epub 2023 Nov 29.

Abstract

Pancreatic cancer (PC) is a common malignant tumour in the digestive system. Due to the lack of sensitive diagnostic markers, strong metastasis ability, and resistance to anti-cancer drugs, the prognosis of PC is inferior. In the past decades, increasing evidence has indicated that the development of PC is closely related to various signalling pathways. With the exploration of RAS-driven, epidermal growth factor receptor, Hedgehog, NF-κB, TGF-β, and NOTCH signalling pathways, breakthroughs have been made to explore the mechanism of pancreatic carcinogenesis, as well as the novel therapies. In this review, we discussed the signalling pathways involved in PC and summarised current targeted agents in the treatment of PC. Furthermore, opportunities and challenges in the exploration of potential therapies targeting signalling pathways were also highlighted.

Keywords: Pancreatic cancer; combined therapy; mechanism; signalling pathways; targeted therapy.

Publication types

  • Review

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Antineoplastic Agents* / therapeutic use
  • Humans
  • Pancreatic Neoplasms* / metabolism
  • Prognosis
  • Signal Transduction

Substances

  • Antineoplastic Agents